Mubritinib

DB12682InvestigationalSmall molecule

Mubritinib has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Formula / weight: C₂₅H₂₃F₃N₄O₂ · 468.48 g/mol (avg)
Code names: TAK-165

Resolves to

Compound

UNIIV734AZP9BRCAS366017-09-6ChEMBLCHEMBL1614707PubChem6444692

Structure

InChIKeyZTFBIUXIQYRUNT-MDWZMJQESA-NSMILESFC(F)(F)C1=CC=C(\C=C\C2=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO2)C=C1

Targets

P04626ERBB2P00533EGFR

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mubritinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account